Affibody is a leading Swedish biotech company focused on developing next generation biopharmaceuticals and affinity proteins based on its unique proprietary technology platform: Affibody® molecules for which it holds intellectual property rights. Affibody has 30 employees focused on development of novel affinity scaffold proteins and several collaborative projects in both EU funded programs (Fp7) and commercial ones.
Supervisor and expertise
Dr. Fredrik Frejd (FF, b1973) is chief scientific officer (CSO) at Affibody as well as adjunct professor in
development of affinity peptides at Uppsala University. Dr Frejd has more than twenty years of experience in developing minimized affinity proteins, and holds a PhD from the Swiss federal institute of technology (ETH), in generation of phage antibody libraries and tumor targeting affinity proteins. He is author/co-author of > 30 publications in peer reviewed journals, several granted patents and several patent applications as well four book chapters.